Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 8/20 | 0.65 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.65 |
| ▸ | GNAO1 | P09471 | 7/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7875482 | 0.88 | GNAI3 (0.59) | GNAI3GNAI1GNAO1NPC1ATM | |
| SCHEMBL25033860 | 0.85 | GNAI3 (0.65) | GNAI3GNAI1GNAO1NPC1ATM | |
| SCHEMBL9224930 | 0.83 | GNAI3 (0.84) | GNAI3GNAI1GNAO1NPC1ATM | |
| SCHEMBL6437826 | 0.82 | NPC1 (0.55) | GNAI3GNAI1GNAO1NPC1ATM | |
| SCHEMBL14417832 | 0.81 | NPC1 (0.81) | GNAI3GNAI1GNAO1NPC1ATM | |
| SCHEMBL2439450 | 0.79 | GNAI3 (0.53) | GNAI3GNAI1GNAO1NPC1CACNA1B | |
| SCHEMBL13180491 | 0.78 | GNAI3 (0.57) | GNAI3GNAI1GNAO1NPC1ATM | |
| SCHEMBL25024582 | 0.78 | GNAI3 (0.57) | GNAI3GNAI1GNAO1NPC1ATM | |
| SCHEMBL1562717 | 0.78 | GNAI3 (0.72) | GNAI3GNAI1GNAO1NPC1CACNA1B | |
| Hydrochloric Acid SCHEMBL1062724 | 0.78 | GNAI3 (0.56) | GNAI3GNAI1GNAO1NPC1CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-7268150-B2 | 2-cyano-4-fluoropyrrolidine derivative or its salt | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-7268150-B2 | 2-cyano-4-fluoropyrrolidine derivative or its salt | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | GNAI3 847/4885GNAI1 511/4885GNAO1 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.